Autopsy report · NCT03090880

Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

“The rate of inclusion is too low to hope to reach the target of 800 patients. 59 patients were included, and their data will not meet the research objectives. The sponsor has decided to prematurely stop inclusions on January 13, 2022.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 6 months before it started.
• Ran for about 2 years 11 months before it stopped.
• 59 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Assistance Publique - Hôpitaux de Paris

Sponsor type

University, hospital or other

Conditions

Venous Thromboembolism; Lung Neoplasm

Interventions

Tinzaparin Sodium

Participants

59

Sites

27

Countries

France

Trials that died the same way

• Cetrotide Treatment Optimization
  “Due to limited rate of patient inclusion” (73% match in meaning)
• Bioavailability of Voriconazole
  “no eligible patients; study stopped without inclusion” (70% match in meaning)
• Rehabilitation in Aortic Stenosis Patients
  “Slow inclusion rate, failure to recruit a priori determined no of patients.” (70% match in meaning)
• Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer
  “Too narrow inclusion criteria. Impossible to recruit patients.” (69% match in meaning)
• Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery
  “Less patients than expected for inclusion, therefore recruitment is too low” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.